The high economic and social costs of diabetes and its rising prevalence, especially the Type 2 diabetes where most adults eventually need to get insulin injections, make a strong case for interventions that improve both the quality of outcomes and costs for diabetes patients. The gene discussed is INS; the disease is diabetes mellitus.